• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].

作者信息

Wang J, Xu H, Chu X X, Wang W

机构信息

Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.

Hematology Department, Yantai Yuhuangding Hospital, Yantai 264000, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):602-605. doi: 10.3760/cma.j.issn.0253-2727.2023.07.016.

DOI:10.3760/cma.j.issn.0253-2727.2023.07.016
PMID:37749045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509612/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b07/10509612/06e86c1a363c/cjh-44-07-602-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b07/10509612/434d0add5840/cjh-44-07-602-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b07/10509612/06e86c1a363c/cjh-44-07-602-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b07/10509612/434d0add5840/cjh-44-07-602-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b07/10509612/06e86c1a363c/cjh-44-07-602-g002.jpg

相似文献

1
[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].硼替佐米、泊马度胺和地塞米松方案治疗复发/难治性多发性骨髓瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):602-605. doi: 10.3760/cma.j.issn.0253-2727.2023.07.016.
2
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
3
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.一项II期试验，旨在研究苯达莫司汀、地塞米松和沙利度胺在接受来那度胺和硼替佐米治疗后的复发或难治性多发性骨髓瘤患者中的疗效和安全性。
Br J Haematol. 2019 Jun;185(5):944-947. doi: 10.1111/bjh.15645. Epub 2018 Nov 26.
4
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.来那度胺联合地塞米松方案治疗硼替佐米和来那度胺治疗后复发/难治性多发性骨髓瘤患者的疗效分析：KMM-166 研究。
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e97-e104. doi: 10.1016/j.clml.2019.10.017. Epub 2019 Oct 31.
5
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.硼替佐米、沙利度胺、地塞米松和帕比司他用于复发多发性骨髓瘤患者（MUK-six）：一项多中心、开放标签的1/2期试验
Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.
6
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.泊马度胺与低剂量地塞米松可改善复发/难治性多发性骨髓瘤患者的健康相关生活质量，并延长MM-003随机III期试验中患者病情恶化的时间。
Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6.
7
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.埃罗妥珠单抗联合泊马度胺、硼替佐米和地塞米松治疗复发难治性多发性骨髓瘤。
Blood Adv. 2025 Mar 11;9(5):1163-1170. doi: 10.1182/bloodadvances.2024014717.
8
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.低剂量沙利度胺联合硼替佐米及地塞米松治疗难治性多发性骨髓瘤
Intern Med. 2016;55(20):3025-3028. doi: 10.2169/internalmedicine.55.6470. Epub 2016 Oct 15.
9
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.达雷妥尤单抗单药治疗与泊马度胺联合低剂量地塞米松治疗多发性骨髓瘤的疗效比较：匹配调整间接比较。
Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.
10
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.优化硼替佐米治疗的多发性骨髓瘤患者的治疗方案。
Expert Rev Hematol. 2018 Jun;11(6):463-469. doi: 10.1080/17474086.2018.1479637. Epub 2018 May 28.

本文引用的文献

1
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.泊马度胺联合低剂量地塞米松治疗中国复发/难治性多发性骨髓瘤患者的有效性和安全性：一项多中心、前瞻性、单臂、Ⅱ期临床试验。
BMC Cancer. 2022 Jul 1;22(1):722. doi: 10.1186/s12885-022-09802-y.
2
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、3 期研究的随访分析。
Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10.
3
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.美国国立综合癌症网络（NCCN）指南见解：多发性骨髓瘤，2022年第3版
J Natl Compr Canc Netw. 2022 Jan;20(1):8-19. doi: 10.6004/jnccn.2022.0002.
4
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
5
Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial.新诊断多发性骨髓瘤患者的肾脏结局：来自英国 NCRI 骨髓瘤 XI 试验的结果。
Blood Adv. 2020 Nov 24;4(22):5836-5845. doi: 10.1182/bloodadvances.2020002872.
6
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.泊马度胺、硼替佐米和地塞米松治疗来那度胺预处理的多发性骨髓瘤（OPTIMISMM）：首次复发时的既往治疗结果。
Leukemia. 2021 Jun;35(6):1722-1731. doi: 10.1038/s41375-020-01021-3. Epub 2020 Sep 7.
7
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.口服方案伊沙佐米、泊马度胺和地塞米松用于复发/难治性多发性骨髓瘤的I/II期试验
Leukemia. 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23.
8
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
9
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.泊马度胺与地塞米松联合环磷酰胺治疗复发/难治性多发性骨髓瘤（AMN001）：亚洲骨髓瘤网络试验。
Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1.
10
Relapsed refractory multiple myeloma: a comprehensive overview.复发难治性多发性骨髓瘤：全面概述。
Leukemia. 2019 Oct;33(10):2343-2357. doi: 10.1038/s41375-019-0561-2. Epub 2019 Aug 27.